ChemoCentryx to Present at the H.C. Wainwright Global Investment Conference
ChemoCentryx will have its CEO, Thomas J. Schall, present at the H.C. Wainwright Global Investment Conference on May 24, 2022, at 12:30 p.m. ET in Miami, FL. The presentation will be available via a live audio webcast on the company’s website, with a replay accessible for two weeks post-event. ChemoCentryx focuses on developing therapies for inflammatory and autoimmune diseases, notably marketing TAVNEOS® for severe active ANCA-associated vasculitis and pursuing treatments for other conditions.
- None.
- None.
SAN CARLOS, Calif., May 16, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the H.C. Wainwright Global Investment Conference on Tuesday, May 24, 2022 at 12:30 p.m. ET. The conference will be held at the Fontainebleau Miami Beach Hotel in Miami, FL.
A live audio webcast of the presentations can be accessed through the Investors section of the Company's website at www.ChemoCentryx.com. A replay of the webcast will be available on the Company's website for two weeks following the live presentation.
About ChemoCentryx
ChemoCentryx is a biopharmaceutical company commercializing and developing new medications for inflammatory and autoimmune diseases and cancer. ChemoCentryx targets the chemokine and chemoattractant systems to discover, develop and commercialize orally administered therapies. In the United States, ChemoCentryx markets TAVNEOS® (avacopan), the first approved orally administered inhibitor of the complement 5a receptor as an adjunctive treatment for adult patients with severe active ANCA-associated vasculitis. TAVNEOS is also in late-stage clinical development for the treatment of severe Hidradenitis Suppurativa (HS) and C3 glomerulopathy (C3G). Additionally, ChemoCentryx has early-stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases and in cancer. For more information about the Company visit www.chemocentryx.com.
TAVNEOS® is a registered trademark of ChemoCentryx, Inc. For more information, please see the Full Prescribing Information and Medication Guide, available at TAVNEOS.com.
Contacts:
Investors:
Bill Slattery, Jr.
Vice President, Investor Relations
& Corporate Communications
650.210.2970
bslattery@chemocentryx.com
Media:
Stephanie Tomei
408.234.1279
media@chemocentryx.com
FAQ
When will ChemoCentryx present at the H.C. Wainwright Global Investment Conference?
Where is the H.C. Wainwright Global Investment Conference being held?
How can I access ChemoCentryx's presentation at the conference?
What is TAVNEOS® and what conditions does it treat?
What other therapies is ChemoCentryx developing?
